79 related articles for article (PubMed ID: 1993552)
1. Tumor-cell lysis by in-situ-activated human peripheral-blood mononuclear cells.
Smans KA; Hoylaerts MF; Hendrickx HF; Goergen MJ; De Broe ME
Int J Cancer; 1991 Feb; 47(3):431-8. PubMed ID: 1993552
[TBL] [Abstract][Full Text] [Related]
2. Requirement of monocytes and T-helper cells during development of tumor cell cytotoxicity in targeted T cells.
Smans KA; Hoylaerts MF; De Broe ME
Cancer Immunol Immunother; 1994 Jan; 38(1):43-52. PubMed ID: 8299118
[TBL] [Abstract][Full Text] [Related]
3. Bispecific antibody-mediated lysis of placental and germ cell alkaline phosphatase targeted solid tumors in immunocompetent mice.
Smans KA; Hoylaerts MF; Narisawa S; Millán JL; De Broe ME
Cancer Res; 1995 Oct; 55(19):4383-90. PubMed ID: 7671251
[TBL] [Abstract][Full Text] [Related]
4. Antibody-dependent, cell-mediated cytotoxicity by an anti-class II murine monoclonal antibody: effects of recombinant interleukin 2 on human effector cell lysis of human B-cell tumors.
Biddle WC; Pancook J; Goldrosen M; Han T; Foon KA; Vaickus L
Cancer Res; 1990 May; 50(10):2991-6. PubMed ID: 2334902
[TBL] [Abstract][Full Text] [Related]
5. The effect of anti-CD3 on the induction of non-MHC restricted cytolytic activity.
Watanabe H; Narumi K; Stewart CC; Arbuck SG; Foon KA; Goldrosen MH
Anticancer Res; 1992; 12(6B):1925-33. PubMed ID: 1295440
[TBL] [Abstract][Full Text] [Related]
6. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
[TBL] [Abstract][Full Text] [Related]
7. Effects of HC antibody in autologous tumor-specific cytotoxicity by human melanoma tumor-infiltrating lymphocytes.
Mansfield PF; Salmeron MA; Rosenblum MG; Itoh K
Int J Cancer; 1991 Sep; 49(3):356-61. PubMed ID: 1917133
[TBL] [Abstract][Full Text] [Related]
8. Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2.
Shiloni E; Eisenthal A; Sachs D; Rosenberg SA
J Immunol; 1987 Mar; 138(6):1992-8. PubMed ID: 3493293
[TBL] [Abstract][Full Text] [Related]
9. Heteroconjugate antibody-directed killing of autologous human renal carcinoma cells by in vitro-activated lymphocytes.
Kerr L; Huntoon C; Donohue J; Leibson PJ; Bander NH; Ghose T; Luner SJ; Vessella R; McKean DJ
J Immunol; 1990 May; 144(10):4060-7. PubMed ID: 2139677
[TBL] [Abstract][Full Text] [Related]
10. Activation of mononuclear cells to be used for hybrid monoclonal antibody-induced lysis of human ovarian carcinoma cells.
Pupa SM; Canevari S; Fontanelli R; Ménard S; Mezzanzanica D; Lanzavecchia A; Colnaghi MI
Int J Cancer; 1988 Sep; 42(3):455-9. PubMed ID: 2971021
[TBL] [Abstract][Full Text] [Related]
11. Lysis of pig endothelium by IL-2 activated human natural killer cells is inhibited by swine and human major histocompatibility complex (MHC) class I gene products.
Itescu S; Artrip JH; Kwiatkowski PA; Wang SF; Minanov OP; Morgenthau AS; Michler RE
Ann Transplant; 1997; 2(1):14-20. PubMed ID: 9869836
[TBL] [Abstract][Full Text] [Related]
12. The role of interleukin 2 in the regulation of proliferation and IgM synthesis of human newborn mononuclear cells.
Punnonen J
Clin Exp Immunol; 1989 Mar; 75(3):421-6. PubMed ID: 2784745
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of HLA-DR antigen expression in phytohemagglutinin-activated T cells in man. Requirement of T cell recognition of self HLA-DR antigen expressed on the surface of monocytes.
Moriya N; Sanjoh K; Yokoyama S; Hayashi T
J Immunol; 1987 Nov; 139(10):3281-6. PubMed ID: 3500214
[TBL] [Abstract][Full Text] [Related]
14. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
15. Lysis of human solid tumor cells by lymphokine-activated natural killer cells.
Itoh K; Tilden AB; Balch CM
J Immunol; 1986 May; 136(10):3910-5. PubMed ID: 3084648
[TBL] [Abstract][Full Text] [Related]
16. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.
Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Stathopoulos GP; Papamichail M
Cancer; 1994 Aug; 74(4):1275-82. PubMed ID: 7914469
[TBL] [Abstract][Full Text] [Related]
17. Cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity mediated by chimeric anti-GD3 monoclonal antibody KM871.
Liu Z; Lee FT; Hanai N; Smyth FE; Burgess AW; Old LJ; Scott AM
Cancer Immun; 2002 Oct; 2():13. PubMed ID: 12747758
[TBL] [Abstract][Full Text] [Related]
18. Lymphokine-activated killer cell cytotoxicity against human colon carcinomas enhanced by monoclonal antibody D612.
Pendurthi TK; Parker R; Schlom J; Primus FJ
Int J Cancer; 1990 Dec; 46(6):1021-8. PubMed ID: 2123477
[TBL] [Abstract][Full Text] [Related]
19. Phenotypic and functional modulation of interleukin-2-activated peripheral blood mononuclear cells by anti-CD3 and anti-CD28 antibody.
Yoshino I; Yano T; Miyamoto M; Sugimachi K; Kimura G; Nomoto K
Lymphokine Cytokine Res; 1993 Aug; 12(4):191-6. PubMed ID: 8218591
[TBL] [Abstract][Full Text] [Related]
20. Injury to autologous normal tissues and tumors mediated by lymphokine-activated killer (LAK) cells generated in vitro from peripheral blood mononuclear cells of glioblastoma patients.
Fujimiya Y; Suzuki Y; Katakura R; Ohno T
J Hematother; 1999 Feb; 8(1):29-37. PubMed ID: 10192299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]